Medicortex USA Ltd. CEO to present at The 2nd TBI-Challenge.eu 2013
Medicortex USA Ltd. CEO to present at The 2nd TBI-Challenge.eu 2013 BIENNIAL INTERDISCIPLINARY CONFERENCE of the BRAIN INJURY AND FAMILIES / EUROPEAN FEDERATION (BIF) on September 19-21, 2013 at the University of Vienna, Austria
[ClickPress, Tue Sep 17 2013] Medicortex USA Ltd. CEO to present at The 2nd TBI-Challenge.eu 2013 BIENNIAL INTERDISCIPLINARY CONFERENCE of the BRAIN INJURY AND FAMILIES / EUROPEAN FEDERATION (BIF) on September 19-21, 2013 at the University of Vienna, Austria.
Traumatic Brain Injury (TBI) is a frequent neurological condition. It represents a worldwide economic burden and its incidence is rapidly growing. TBI is difficult to diagnose because of the many different performances in each individual after the trauma and for the late stage clinical signs appearance upon the primary TBI incident. TBI involves the injured patient, his/her immediate family, the social environment, as well as the health facilities and social security services. In addition, as yet no drug is available to address the progression of the secondary injury to the brain upon TBI.
Dr. Adrian Harel, Medicortex’s owner and CEO, stated: “I will attend and present the developing plan of our new drug candidates, which are aimed to moderate the effects of TBI. The company has designed three chemically verified proprietary NCE’s, each with lipophilic properties for crossing the brain-blood-barrier, and possessing at least two neuroprotective functions, such as free metal ion binding, anti-oxidation, anti-inflammation, and/or anti-bacterial. I will present the research plan for the initial studies assessing the biological activity and lack of toxicity of its pipeline compounds.”
TBI is a complex condition, in which various different biochemical pathways are impaired, thereby causing a multi-system neurodegenerative disorder. The complexity of TBI is perhaps the reason that TBI clinical trials testing a drug aimed to a single target, have failed to reach their endpoints. It is estimated that the TBI therapeutics market will grow at 3.8% annually for the next 4 years, reaching $2 billion by 2017. According to the National Centers for Disease Control (CDC), there are approximately one million TBI incidents in the US each year. Of these, an estimated 5% - 15% suffer from moderate to severe permanent brain impairment. Secondary brain injury in patients with severe or mild TBI occurs as a result of increased permeability of the neuronal membrane, followed by an excessive influx of metal ions and circulating free radicals. This causes a series of protein degradation cascades and oxidation, leading to widespread molecular damage and neuronal cell death. The outcomes of this chain of events include permanent disability and even death.
Medicortex is an innovative, proof-of-concept biotechnology company developing breakthrough drug agents for the treatment of TBI, stroke, toxic nerve agent exposure, and other acute neurodegenerative conditions. The company's initial focus is on preventing secondary brain injury in TBI, a complex process caused by the multitude biochemical changes upon the primary injury. MediCortex's unique neuroprotective strategy is to introduce a multi-functional compound that addresses several biochemical and physiological pathways simultaneously. Medicortex is a privately held company founded in 2010 by Dr. Adrian Harel, an experienced neurobiologist with a track record in business management and in the leadership of early-stage drug discovery companies. His collaboration with renowned experts in medicinal chemistry promises the establishment of a successful pipeline of innovative molecules for the treatment of acute neurodegenerative disorders.
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements involving risks and uncertainties, Actual results may differ materially from the results anticipated in these forward-looking statements.
Dr. Adrian Harel, CEO